TribLIVE

| USWorld


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

FDA grants approval for multiple sclerosis medication

About The Tribune-Review
The Tribune-Review can be reached via e-mail or at 412-321-6460.
Contact Us | Video | Photo Reprints

Daily Photo Galleries


By The Los Angeles Times

Published: Thursday, March 28, 2013, 6:33 p.m.

WASHINGTON — An oral medication for multiple sclerosis has won the Food and Drug Administration's marketing approval and is to become available almost immediately to patients suffering from the debilitating auto-immune disease.

Tecfidera is the commercial name for dimethyl fumarate, a capsule that won the FDA's blessing this week as a treatment for relapsing MS, a degenerative brain disorder that can impair mobility, sensation and thinking.

In clinical trial evidence submitted to the FDA by Biogen Idec of Weston, Mass., the medication's maker, Tecfidera reduced the proportion of patients who relapsed when compared with a sham medication. In one of those trials, subjects taking Tecfidera showed less progression of the disease compared with those on a placebo. And both trials found that those taking Tecfidera twice daily developed fewer MS-related lesions in the brain.

The medication was formerly known as BG-12.

Those findings held whether patients had newly diagnosed multiple sclerosis or had their multiple sclerosis progress over some years, said Dr. Robert M. Fox, medical director of the Mellen Center for Multiple Sclerosis at the Cleveland Clinic, in a statement issued by Biogen Idec. Fox serves as a paid adviser to the firm and was lead investigator in one of the Tecfidera's earliest trials.

Common side effects of Tecfidera are flushing and gastrointestinal events, including nausea, diarrhea and vomiting. And though no increased rate of infections were noted in those taking Tecfidera in clinical trials, the medication may lower white blood counts and increase infection risk, the FDA said.

 

 
 


Show commenting policy

Most-Read Nation

  1. Hearing to determine fate of sergeant accused of killing 2 deaf Iraqi youths
  2. Mo. mayor steps down over anti-Semitic comments
  3. Senator pitches gasoline tax increase
  4. Precautions lack year since fatal blast at plant
  5. Little toxicity data exists for tainted W.Va. water
  6. Foundation gives $13M to promote Obamacare
  7. Justices critical of Ohio law punishing campaign lies
  8. Justices uphold Michigan ban on affirmative action, giving states room to maneuver
  9. Details about USS Cole suspect’s stint in CIA custody must be turned over
  10. Moscow to get serious ‘message’ from U.S.
  11. IRS awards millions in bonuses to its people who don’t pay taxes
Subscribe today! Click here for our subscription offers.